- Open Access
Correction to: Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*
© The Author(s). 2019
- Received: 6 February 2019
- Accepted: 6 February 2019
- Published: 22 February 2019
The original article was published in BMC Pharmacology and Toxicology 2019 20:5
Correction to: BMC Pharmacol Toxicol (2019) 20:5
Following publication of the original article , the author reported their given name have been erroneously tagged as their family names.
The correct list is:
Given name Nahum Family name Méndez-Sánchez, Given name Miguel Family name Dibildox-Martinez, Given name Jahir Family name Sosa-Noguera Jahir, Given name Ramón Family name Sánchez-Medal, Given name Francisco J. Family name Flores-Murrieta.
It has been corrected in the original article as well.
The publisher apologizes for any inconvenience caused by this error.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Méndez-Sánchez N, Dibildox-Martinez M, Sosa-Noguera J, Sánchez-Medal R, et al. Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*. BMC Pharmacol Toxicol. 2019;20:5. https://doi.org/10.1186/s40360-018-0280-8.